Sildenafil for Post-capillary Pulmonary Hypertension in Patients Undergoing Cardiac Surgery

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Pulmonary hypertension increases the perioperative risk in patients undergoing cardiac surgery for valvular heart diseases, especially in patients with a long life mitral valve disease. The present study wants to test the hypothesis that intravenous administration of sildenafil reduces pulmonary vascular resistances and afterload of the right ventricle.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Turin, Italy
• Treatments: Sildenafil Citrate

Criteria

Inclusion Criteria:

• all patients undergoing valvular heart surgery associated to post capillary pulmonary hypertension with a mean pulmonary arterial pressure (mPAP)>30mmHg or pulmonary vascular resistance (PVR)>3Wu.

Exclusion Criteria:

• patients younger than 18 years old

• ischemic cardiomyopathy

• Ejection Fraction (EF)<30%

• severe Chronic obstructive pulmonary disease (COPD) with oxygen and bronchodilators therapy

• chronic pulmonary disease, chronic renal failure on dialysis

• hepatic failure

• patients with orotracheal intubation and already admitted to the ICU before the intervention